N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR)
Clinical Scorecard: N-acetylcysteine: A Consensus Document on Its Therapeutic Benefits in Respiratory Disorders Based on Evidence (NECTAR)
At a Glance
| Category | Detail |
|---|
| Condition | Chronic respiratory disorders |
| Key Mechanisms | Antioxidant, anti-inflammatory, immunomodulatory, and anti-biofilm effects |
| Target Population | Patients with stable COPD, AECOPD, tuberculosis, non-cystic fibrosis bronchiectasis, cystic fibrosis, and respiratory infections |
| Care Setting | Clinical practice |
Key Highlights
- NAC is effective as an adjunct therapy in COPD, especially for preventing exacerbations.
- In cystic fibrosis, NAC improves lung function and mucociliary clearance.
- NAC is safe and well-tolerated across various respiratory conditions.
- Further evidence is needed for NAC's efficacy in asthma and interstitial lung disease.
- NAC may reduce exacerbations in non-CF bronchiectasis.
Guideline-Based Recommendations
Diagnosis
- Consider NAC in patients with chronic respiratory diseases for its antioxidant properties.
Management
- Use NAC at 600 mg twice daily for COPD to prevent exacerbations.
- Administer low-dose NAC during acute exacerbations of COPD.
Monitoring & Follow-up
- Monitor lung function and exacerbation frequency in patients receiving NAC.
Risks
- NAC is generally safe; however, further studies are needed to clarify its role in asthma and ILDs.
Patient & Prescribing Data
Patients with chronic respiratory conditions including COPD, bronchiectasis, and cystic fibrosis.
NAC can enhance treatment outcomes by improving mucociliary clearance and reducing oxidative stress.
Clinical Best Practices
- Integrate NAC into treatment plans for chronic respiratory diseases where appropriate.
- Educate patients on the benefits and safety of NAC.
References
